Latest News

Cleveland, Ohio – Findings from a trial led by Cleveland Clinic show that patients with atrial fibrillation undergoing a transcatheter aortic valve replacement (TAVR) at the same time as a left atrial appendage occlusion (LAAO) procedure using the Watchman™ device had similar outcomes when compared to patients getting TAVR in...
WELLESLEY HILLS, Mass. — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced results from a completed nonhuman primate (NHP) study comparing CLYM116 to sibeprenlimab, a first-generation anti-APRIL monoclonal antibody. The company is hosting a virtual investor event focused on CLYM116 today, Monday,...
SAN DIEGO, Calif. – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE...
Clinical trial diversity is not a new concept–the U.S. Food and Drug Administration (FDA) issued a draft guidance providing specific recommendations to industry on how to improve diversity in clinical trials in April 2022 but the passage of the Food and Drug Omnibus Reform Act, or FDORA, highlighted that the...
London, England – A collaboration of researchers, led by UCL and Great Ormond Street Hospital, have published successful results from a Phase II clinical trial for the treatment of BRAF mutated low-grade paediatric gliomas. Gliomas are cancerous brain tumours that start in glial cells – the supporting cells of the...